Operon Biotechnologies And DNA2.0 Announce Comarketing And Technology Development Partnership
DNA2.0 Inc. (www.DNA20.com), the largest US provider of synthetic genes, and Operon Biotechnologies(www.operon.com), a leader in DNA oligonucleotide synthesis, announce the formation of a partnership to utilize their synergistic technologies and product lines.
By combining Operon's oligonucleotide production platform with DNA2.0's gene synthesis process, the companies expect to further increase DNA2.0's market leading speed of synthesis, while providing Operon access to the fastest growing application area for oligonucleotides today. The partnership will allow each company to remain focused on their respective core businesses, while the customer benefits from the expertise of both partners.
Under the partnership, Operon will co-market DNA2.0’s gene synthesis services. ‘DNA2.0 provides products and a level of customer service that is unparalleled in the gene synthesis industry, we wholeheartedly recommend them to our customers for their synthetic genes.’ said Patrick A. Weiss, CEO of Operon. ‘We at Operon are proud to be the primary source of the oligos that go into DNA2.0 synthetic genes.’
‘Construction of synthetic genes requires oligos of only the highest quality’ said Jeremy Minshull, President of DNA2.0. ‘Operon's fully automated oligo synthesis process meets our exacting quality requirements, and their speed and responsiveness makes Operon an outstanding partner for DNA2.0 in the gene synthesis marketplace.’
About DNA2.0, Inc.
DNA2.0 is the largest US provider of synthetic genes, serving customers globally in the pharmaceutical and biotechnology industries as well as in academia. The company is also pioneering the application of machine learning to commercial protein engineering through their ProteinGPS™ platform. For more information please visit www.DNA20.com.
About Operon Biotechnologies
Operon Biotechnologies is a global market leader in high-throughput synthesis, serving scientists in academic research, biotechnology, and pharmaceutical development. Through our production facilities in the US, Germany, and Japan, as well as distributors worldwide, Operon provides a wide range of quality DNA oligonucleotides, Array Ready Oligo Sets (AROS™) and pre-printed microarrays (OpArray™). Since its inception in 1986, Operon has been driven by incomparable customer service and reliable delivery of quality products. Operon employs advanced synthesis technologies and consistently pursues unique innovations to maintain the highest level of excellence in both products and support. For more information, please visit www.operon.com.